Connect Biopharma Holdings Ltd (CNTB)
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $64.0K
- Net income
- -$55.5M
- Total assets
- $56.1M
- Market cap
- $134.7M
- Operating margin
- -90740.6%
- Net margin
- -86687.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $64.0K
- Operating expenses
- $58.1M
- Operating income
- -$58.1M
- Income tax
- $197.0K
- Net income
- -$55.5M
- EPS (basic)
- $-1.00
- EPS (diluted)
- $-1.00
Balance sheet
- Total assets
- $56.1M
- Current assets
- $50.9M
- Total liabilities
- $14.1M
- Current liabilities
- $13.6M
- Shareholders’ equity
- $42.0M
Cash flow
- Operating cash flow
- -$51.2M
- Investing cash flow
- $9.8M
- Financing cash flow
- $1.1M
- Net cash flow
- -$39.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $134.7M
- EPS (diluted)
- $-1.0
- Shares outstanding
- 63.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 3, 2025
Connect Biopharma Holdings Ltd (CNTB) Stock Price
- Reported a net loss of $55.5M in FY2025.
- Revenue declined 100% from FY2024 to FY2025.
- Trading 42% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Connect Biopharma Holdings Ltd.
Write a review
News about Connect Biopharma Holdings Ltd
News & sentiment via Polygon.io
Connect Biopharma Holdings Ltd: frequently asked questions
Is Connect Biopharma Holdings Ltd an American company?
Connect Biopharma Holdings Ltd is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Connect Biopharma Holdings Ltd headquartered?
Connect Biopharma Holdings Ltd is headquartered in San Diego, California, United States.
Is Connect Biopharma Holdings Ltd publicly traded?
Yes — Connect Biopharma Holdings Ltd is a publicly traded company. Its stock trades under the ticker symbol CNTB on the NASDAQ.
What does Connect Biopharma Holdings Ltd do?
Connect Biopharma Holdings Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
